In this high-impact scientific communication a research team from Inserm, CNRS, Institut Paoli-Calmettes, Aix Marseille University, France, identified genes regulating breast cancer stem cells (bCSC) from a genome-wide RNA interference screen. From their findings, they investigated the therapeutic potency of a synergistic drug treatment combining salinomycin (autophagy regulator) and JQ1 (transcriptional mediator complex inhibitor) in a model of patients-derived primary breast cancer xenografts (PDX). Using the PhotonIMAGER Optima system, they could quantify the effect of JQ1/salinomycin treatment on metastasis formation from triple-negative breast cancer cells (CRCM404 and CRCM434) orthotopically transplanted into the fat pads of immunodeficient (NSG) mice. The salinomycin/JQ1 combination significantly reduced metastasis in both PDX models with almost complete eradication of bCSC cells in secondary tumors. The authors concluded that salinomycin/JQ1 combination may provide the basis for a new therapeutic approach in the treatment of breast cancer.
Abir Arfaoui, Claire Rioualen, Violette Azzoni, Guillaume Pinna, Pascal Finetti, Julien Wicinski, Emmanuelle Josselin, Manon Macario, Rémy Castellano, Candi Léonard-Stumpf, Anthony Bal, Abigaelle Gros, Sylvain Lossy, Maher Kharrat, Yves Collette, Francois Bertucci, Daniel Birnbaum, Hayet Douik, Ghislain Bidaut, Emmanuelle Charafe-Jauffret & Christophe Ginestier.
Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Aix-Marseille University, Marseille, France